INTRODUCTION AND OBJECTIVES: Assessment of the cost-effectiveness of dabigatran for
the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation …

Abstract Introduction and Objectives To estimate the cost-effectiveness and cost-utility of
dabigatran in the prevention of stroke and systemic embolism in patients with non-valvular …

Background Atrial fibrillation is the main cause of stroke, but the risk can be reduced, usually
with vitamin K antagonists (VKAs) such as warfarin. The RE-LY atrial fibrillation study …

Introduction: The objective of the present study was to evaluate, from an economic
perspective, dabigatran etexilate in comparison to existing pharmaceutical therapeutic …

Objectives: Atrial fibrillation is a major risk factor for ischemic stroke and anticoagulation
therapy is indicated to reduce risk. Dabigatran is a new oral anticoagulant that does not …

Objective: To estimate the economic implications of introducing dabigatran etexilate
('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial …

Objective: To assess the cost-effectiveness of dabigatran etexilate ('dabigatran') vs vitamin K
antagonists (VKAs) in the Belgian healthcare setting for the prevention of stroke and …

Aims Patients with atrial fibrillation have a significantly increased risk of thromboembolic
events such as ischaemic stroke, and patients are therefore recommended to be treated with …

Background. Dabigatran is an oral anticoagulant direct thrombin inhibitor recently registered
in South Africa (SA) to reduce the risk of stroke and systemic embolism in patients with atrial …

Objective To analyze the cost-effectiveness and cost-utility of dabigatran compared with
warfarin in patients with nonvalvular atrial fibrillation with moderate to high risk of ischemic …